---
title: "Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292794714.md"
description: "Celcuity's stock experienced a significant drop on Wednesday following the announcement that the biotech company would be postponing the release of its recently approved breast cancer therapy until the third quarter. This delay resulted in a double-digit decrease in their stock value, highlighting the challenges they are currently facing despite securing their first FDA approval. The latest setback raises concerns about the company's performance and its ability to meet market expectations."
datetime: "2026-07-15T15:41:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292794714.md)
  - [en](https://longbridge.com/en/news/292794714.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292794714.md)
generator: "portal-rs"
---

# Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits

Celcuity's stock experienced a significant drop on Wednesday following the announcement that the biotech company would be postponing the release of its recently approved breast cancer therapy until the third quarter. This delay resulted in a double-digit decrease in their stock value, highlighting the challenges they are currently facing despite securing their first FDA approval. The latest setback raises concerns about the company's performance and its ability to meet market expectations.

### Related Stocks

- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)

## Related News & Research

- [Celcuity Analysts Slash Their Forecasts After Q2 Loss](https://longbridge.com/en/news/295935858.md)
- [Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295849905.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT](https://longbridge.com/en/news/296675400.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**